184 related articles for article (PubMed ID: 9794495)
1. Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells.
Li S; Deshmukh HM; Huang L
Pharm Res; 1998 Oct; 15(10):1540-5. PubMed ID: 9794495
[TBL] [Abstract][Full Text] [Related]
2. Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes.
Chiu SJ; Marcucci G; Lee RJ
Anticancer Res; 2006; 26(2A):1049-56. PubMed ID: 16619505
[TBL] [Abstract][Full Text] [Related]
3. Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles.
Zhou W; Yuan X; Wilson A; Yang L; Mokotoff M; Pitt B; Li S
Bioconjug Chem; 2002; 13(6):1220-5. PubMed ID: 12440856
[TBL] [Abstract][Full Text] [Related]
4. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo.
Leamon CP; Cooper SR; Hardee GE
Bioconjug Chem; 2003; 14(4):738-47. PubMed ID: 12862426
[TBL] [Abstract][Full Text] [Related]
5. Growth of ovarian-carcinoma cell lines at physiological folate concentration: effect on folate-binding protein expression in vitro and in vivo.
Miotti S; Facheris P; Tomassetti A; Bottero F; Bottini C; Ottone F; Colnaghi MI; Bunni MA; Priest DG; Canevari S
Int J Cancer; 1995 Nov; 63(3):395-401. PubMed ID: 7591238
[TBL] [Abstract][Full Text] [Related]
6. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels.
Rait AS; Pirollo KF; Xiang L; Ulick D; Chang EH
Mol Med; 2002 Aug; 8(8):475-86. PubMed ID: 12435858
[TBL] [Abstract][Full Text] [Related]
7. Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor.
Theti DS; Bavetsias V; Skelton LA; Titley J; Gibbs D; Jansen G; Jackman AL
Cancer Res; 2003 Jul; 63(13):3612-8. PubMed ID: 12839949
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment.
Jhaveri MS; Rait AS; Chung KN; Trepel JB; Chang EH
Mol Cancer Ther; 2004 Dec; 3(12):1505-12. PubMed ID: 15634643
[TBL] [Abstract][Full Text] [Related]
9. Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro.
Sen S; Erba E; D'Incalci M; Bottero F; Canevari S; Tomassetti A
Br J Cancer; 1996 Feb; 73(4):525-30. PubMed ID: 8595169
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines.
Miotti S; Bagnoli M; Ottone F; Tomassetti A; Colnaghi MI; Canevari S
J Cell Biochem; 1997 Jun; 65(4):479-91. PubMed ID: 9178098
[TBL] [Abstract][Full Text] [Related]
11. [Study on the tumor cell targetability of folate-conjugated albumin nanoparticles].
Zhang LK; Hou SX; Mao SJ; Wei DP; Song XR; Qiao XR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Mar; 35(2):165-8. PubMed ID: 15071905
[TBL] [Abstract][Full Text] [Related]
12. Phosphorothioate oligodeoxynucleotides inhibit basic fibroblast growth factor-induced angiogenesis in vitro and in vivo.
Kitajima I; Unoki K; Maruyama I
Antisense Nucleic Acid Drug Dev; 1999 Apr; 9(2):233-9. PubMed ID: 10355829
[TBL] [Abstract][Full Text] [Related]
13. Propynylated phosphodiester oligonucleotides inhibit ICAM-1 expression in A549 cells on electroporation.
Meunier L; Monsigny M; Roche AC
Antisense Nucleic Acid Drug Dev; 2001 Apr; 11(2):117-23. PubMed ID: 11334140
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of antisense oligodeoxynucleotides to folate receptor-overexpressing tumor cells.
Yang L; Li J; Zhou W; Yuan X; Li S
J Control Release; 2004 Mar; 95(2):321-31. PubMed ID: 14980780
[TBL] [Abstract][Full Text] [Related]
15. Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor.
Wiener EC; Konda S; Shadron A; Brechbiel M; Gansow O
Invest Radiol; 1997 Dec; 32(12):748-54. PubMed ID: 9406015
[TBL] [Abstract][Full Text] [Related]
16. Targeted drug delivery to chemoresistant cells: folic acid derivatization of FdUMP[10] enhances cytotoxicity toward 5-FU-resistant human colorectal tumor cells.
Liu J; Kolar C; Lawson TA; Gmeiner WH
J Org Chem; 2001 Aug; 66(17):5655-63. PubMed ID: 11511236
[TBL] [Abstract][Full Text] [Related]
17. Folate receptor-mediated cancer cell specific gene delivery using folic acid-conjugated oligochitosans.
Lee D; Lockey R; Mohapatra S
J Nanosci Nanotechnol; 2006; 6(9-10):2860-6. PubMed ID: 17048492
[TBL] [Abstract][Full Text] [Related]
18. Receptor-targeted gene delivery via folate-conjugated polyethylenimine.
Guo W; Lee RL
AAPS PharmSci; 1999; 1(4):E19. PubMed ID: 11741215
[TBL] [Abstract][Full Text] [Related]
19. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro.
Lee RJ; Low PS
Biochim Biophys Acta; 1995 Feb; 1233(2):134-44. PubMed ID: 7865538
[TBL] [Abstract][Full Text] [Related]
20. Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells.
Wang S; Low PS
J Control Release; 1998 Apr; 53(1-3):39-48. PubMed ID: 9741912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
